Emergent BioSolutions (EBS) Non-Current Deffered Revenue (2010 - 2022)
Emergent BioSolutions (EBS) posted Non-Current Deffered Revenue of $5.9 million for Q1 2022, up 25.53% on a QoQ basis from $4.7 million in Q4 2021, and down 88.76% year-over-year from $52.5 million in Q1 2021.
Powered by 
Analysis
Emergent BioSolutions (EBS) Non-Current Deffered Revenue (2010 - 2022) Analysis & Trends
Emergent BioSolutions has reported Non-Current Deffered Revenue for 11 years, with the latest figure at $5.9 million in Q1 2022.
- On a quarterly basis, Non-Current Deffered Revenue fell 88.76% year-over-year to $5.9 million in Q1 2022; TTM through Mar 2022 was $5.9 million, a 88.76% decrease from a year earlier, with the FY2021 full-year figure at $4.7 million, down 91.53% from the prior year.
- Non-Current Deffered Revenue was $5.9 million for Q1 2022 at Emergent BioSolutions, up from $4.7 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $85.6 million in Q4 2019, with the low at $4.7 million in Q4 2021.
- Average Non-Current Deffered Revenue over 5 years is $59.0 million, with a median of $62.5 million recorded in 2018.
- The sharpest annual moves came in 2018 and 2021: Non-Current Deffered Revenue surged 327.49% in 2018, then sank 91.53% in 2021.
- Over 5 years, Non-Current Deffered Revenue stood at $62.5 million in 2018, then surged by 36.96% to $85.6 million in 2019, then slumped by 35.16% to $55.5 million in 2020, then tumbled by 91.53% to $4.7 million in 2021, then increased by 25.53% to $5.9 million in 2022.
- The last three Non-Current Deffered Revenue figures came in at $5.9 million (Q1 2022), $4.7 million (Q4 2021), and $45.3 million (Q3 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn | - |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn | - |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn | - |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn | - |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - | - |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | 5.90 Mn |
| Dec 31, 2021 | 4.70 Mn |
| Sep 30, 2021 | 45.30 Mn |
| Jun 30, 2021 | 48.90 Mn |
| Mar 31, 2021 | 52.50 Mn |
| Dec 31, 2020 | 55.50 Mn |
| Sep 30, 2020 | 60.40 Mn |
| Jun 30, 2020 | 85.30 Mn |
| Mar 31, 2020 | 85.00 Mn |
| Dec 31, 2019 | 85.60 Mn |
| Sep 30, 2019 | 81.60 Mn |
| Jun 30, 2019 | 77.00 Mn |
| Mar 31, 2019 | 64.70 Mn |
| Dec 31, 2018 | 62.50 Mn |
| Sep 30, 2018 | 65.34 Mn |
| Jun 30, 2018 | 63.26 Mn |
| Mar 31, 2018 | 59.37 Mn |
| Dec 31, 2017 | 17.30 Mn |
| Sep 30, 2017 | 24.97 Mn |
| Jun 30, 2017 | 17.09 Mn |
API Access
Emergent BioSolutions Non-Current Deffered Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "non-current-deffered-revenue", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();